Gp-1 Dipeptidyl Peptidase-4 Inhibitors

Inhibitorsofdipeptidylpeptidase4(DPP-4inhibitorsor gliptins) are a class of oral hypoglycemics that block the enzymedipeptidylpeptidase-4(DPP-4). They can be used to treat diabetes mellitus type 2.

Dipeptidylpeptidase4(DPP-4)inhibitors, or gliptins, are oral antidiabetic medications that enhance the production of incretin by inhibiting the degradation of endogenous “insulinotropic” GIP and G.

Dipeptidylpeptidase-4(DPP-4)inhibitorsare one of two classes of antidiabetes drugs that mediate their glucose-lowering effect through the incretin pathway. They are administered orally and offer significant glucose-lowering with a neutral weight profile and a low risk of hypoglycaemia.

Dipeptidylpeptidase-4(DPP-4)inhibitorshave been. shown to reduce blood pressure in many studies.42. FadiniGP, Avogaro A (2013)Dipeptidylpeptidase-4inhibition. and vascular repair by mobilization of endogenous stem cells in. diabetes and beyond.

Additionally, the potential impact ofdipeptidylpeptidase-4inhibitors(DPP-4Is) on alcohol intake is largely unknown. Methods: We conducted a large cohort study using 2008-2023 electronic health records data from the U.S. Department of Veterans Affairs.

Concerns have been raised thatdipeptidyl-peptidase4inhibitors(DPP-4i) may increase the risk of pneumonia. We analysed observational data and clinical trials to explore whether use of DPP-4i modifies the risk of pneumonia.

Orally administeredDipeptidylPeptidase-4inhibitorsreduce hemoglobin A1c by 0•5-1•0%, with few adverse effects and no weight gain. These new classes of anti-diabetic agents also expand β-cell mass in preclinical studies.

Dipeptidylpeptidase‐4inhibitorsare effective in populations where the islet dysfunction is a critical key for hyperglycemia in type 2 diabetes, including individuals of East Asian origin.